Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Probiotic supplement plus lifestyle changes for fatty liver (MASLD)

Official title: Impact of a Multi-strain Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Run by Fu Jen Catholic University Hospital · NCT07400367 · Data updated 2026-11-12

This trial will test whether taking a probiotic supplement alongside lifestyle changes can reduce liver fat, improve liver tests, and improve metabolic health in adults with MASLD.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment80 (estimated)
SponsorFu Jen Catholic University Hospital
Academic / other
Drugs / interventionsMethotrexate
Locations2 sites (New Taipei City and 1 other locations)
StatusRecruiting
StartedApril 1, 2026
Main results expectedMay 2027
Study endsAugust 2027
Registry record updatedApril 6, 2026
Trial IDNCT07400367 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with ultrasound-confirmed liver steatosis, ALT ≥ 60 U/L, and at least one cardiometabolic risk factor (for example elevated BMI, hypertension, dyslipidemia, or impaired glucose) are the intended participants.

Probably not a fit

People with active viral hepatitis, established cirrhosis, excessive alcohol intake, recent antibiotic use, suspected autoimmune or drug-induced hepatitis, or who are taking medications that induce liver steatosis are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with MASLD and elevated ALT who have ultrasound-confirmed liver steatosis will receive a structured lifestyle modification program and be given either an oral probiotic product or a placebo. Key outcomes include liver steatosis and fibrosis measured by elastography, liver enzymes, and metabolic markers such as fasting glucose, HbA1c, lipids, and measures of insulin resistance. Common exclusions include viral hepatitis, cirrhosis, heavy alcohol use, recent antibiotics, autoimmune or drug-related hepatitis, and use of medications known to induce steatosis. The trial aims to determine whether adding a probiotic to lifestyle change provides measurable benefits beyond lifestyle change alone.

Why it matters

Potential benefit: If successful, adding a probiotic to lifestyle therapy could offer a low-risk, accessible way to lower liver fat and improve metabolic and liver-related measures in people with MASLD.

How similar studies have gone: Previous small trials of probiotics in NAFLD/MASLD populations have reported mixed but sometimes modest improvements in liver enzymes and steatosis, so the approach is promising but not yet definitive.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ALT ≥ 60 U/L
* Liver steatosis identified by ultrasound
* Meet at least one cardiometabolic criteria:

  1. BMI ≥ 25 kg/m2 (Asian ≥23)
  2. Waist circumference: \> 94cm (M) 80cm(F)
  3. Fasting blood glucose ≥ 100 mg/dL
  4. HbA1c ≥ 5.7
  5. Receiving treatment of diabetes
  6. Receiving treatment of Hypertension
  7. Average home blood pressure: ≥ 130/85 mmHg
  8. TG ≥ 150 mg/dL
  9. HDL ≤ 40 mg/dL
  10. Receiving treatment of dyslipidemia

Exclusion Criteria:

* HBsAg(+)
* Anti-HCV (+)
* Cirrhosis
* Excessive alcohol intake ( Male over 210g/wk; Female over 140mg/wk)
* Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+))
* Could not rule out drug related hepatitis
* Receiving drug that might induce liver steatosis:
* Glucocorticoids
* Amiodarone
* Tamoxifen
* Methotrexate
* Valproate
* Tetracycline
* Chemotherapeutic agents
* Receiving immune modulators or biologics
* Receiving antibiotics within 1 month
* Receiving any cancer treatment
* Have diagnosis of "Catastrophic Illness" defined by Health Administration of Taiwan
* eGFR\<60
* Pregnancy
* Currently enrolled in other dietary or pharmacology clinical trial

Where it's running

  • Fu Jen Catholic University Hospital
    New Taipei City, Taiwan
    Recruiting
  • Fu Jen Catholic University Hospital
    New Taipei City, Taiwan
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.